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Abstract: This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV)-infected patients
from Buenos Aires, Argentina, and to determine their effect on therapy outcome. Additionally,
virological, clinical and host genetic factors were explored as predictors of the presence of baseline
RASs. NS3 RASs (39.2%) were more prevalent than NS5A RASs (25%) and NS5B RASs (8.9%).
In the three regions, the frequencies of RASs were significantly higher in HCV-1b than in HCV-1a.
The prevalence of Y93H, L159F and Q80K were 1.3%, 6.3% and 2.5%, respectively. IFNL3 CC genotype
was identified as an independent predictor of the presence of baseline RASs in NS5A and NS3 genes
(p = 0.0005 and p = 0.01, respectively). Sustained virologic response was achieved by 93.3% of the
patients after receiving direct-acting antivirals (DAAs), although 48.7% of them showed baseline RASs
related to the DAA-regimen. Notably, the prevalence of clinically relevant RASs in the three genes
was lower than that observed around the world. The baseline presence of RASs in both subtypes did
not appear to affect therapy outcome. These results support the need to evaluate resistance patterns
in each particular country since RASs´ prevalence significantly vary worldwide.
Keywords: hepatitis C virus; resistance-associated substitutions; direct-acting antivirals; quasispecies
1. Introduction
Hepatitis C Virus (HCV) infection affects more than 70 million people worldwide [1,2]. Argentina
is considered a low-endemicity country, with a prevalence that is estimated to be around 1% [3];
although higher rates have been described in different small rural communities [4].
The treatment of chronic HCV infection has considerably improved in recent years with the
widespread development of “direct-acting antiviral” (DAA) drugs. These drugs, which target specific
viral proteins of the HCV lifecycle, can be combined in highly effective, well-tolerated, interferon-free
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treatment regimens [5,6]. Currently available HCV DAAs are classified into four categories on the
basis of their molecular target in the viral replication cycle and mechanism of action: NS3/4A protease
inhibitors, NS5A inhibitors, nucleotide analogue inhibitors of NS5B RNA-dependent RNA polymerase
(RdRp), and non-nucleoside inhibitors of RdRp. Each drug family has a specific resistance profile that
influences the barrier to resistance and may vary among HCV genotypes and subtypes [7,8]. In this
regard, different combinations of simeprevir (SMV), sofosbuvir (SOF), paritaprevir (PTV), daclatasvir
(DCV), ledipasvir (LDV), ombitasvir (OMV), dasabuvir (DSV), velpatasvir (VLP), grazoprevir (GZR)
and elbasvir (ELB), have already been approved by the regulatory system and are currently available
in Argentina [9].
Despite the high rates of sustained virologic response (SVR) (over 90%), the effectiveness of new
DAAs may be compromised by the emergence of resistance-associated variants (RAVs) [6,10–12].
The development of drug resistance is indeed an intrinsic, and to some extent unavoidable,
characteristic of antiviral therapies. The combination of the high replication rate of HCV, along with
the low fidelity and the lack of proof-reading mechanisms of its RNA dependent RNA polymerase,
results in a highly variable viral population known as “quasispecies” within each infected individual.
This large heterogeneity in viral gene sequences and natural dynamic variability promotes the rapid
emergence of RAVs [13].
An RAV is defined by the presence of one or more resistance-associated substitutions (RASs),
amino acid substitutions able to adversely impact the activity of DAAs in vitro and/or in vivo in
treated patients [14]. Resistance-associated substitutions (RASs) may arise during therapy or may
pre-exist at baseline, increasing the likelihood of treatment failure [6,10–12,15]. In particular, natural
changes in HCV NS3, NS5A and NS5B genes associated with reduced drug sensitivity have been
observed in DAA treatment-naïve patients [6]. Therefore, even prior to treatment, RAVs may exist
as minor variants at baseline, which would rapidly become dominant under the selective pressure
exerted by the drugs, subsequently leading to a virological breakthrough during treatment or a relapse
after treatment cessation [6,14].
The prevalence of these naturally occurring RASs has been examined using standard population
(Sanger) sequencing. Unfortunately, this conventional method is not sensitive enough in detecting
clinically relevant variants present in less than 20% of the viral population [16]. In this regard,
next-generation sequencing (NGS) technologies have demonstrated to be a useful tool to detect minor
variants at baseline [17].
The utility of RAS testing depends upon both patient characteristics and DAA regimen. At present,
RASs detection at baseline is particularly important in patients infected with HCV genotypes 1a and
3 [12]. Even though treatment-associated RASs are clinically more important than natural RASs,
the latter might negatively impact treatment with some regimens like ELB/GZR and SMV/SOF in
patients infected with genotype 1a [12]. Nevertheless, until newer DAAs become extensively available
in all countries, and the issue of resistance will not be overcome, the HCV genotypic resistance testing
is, and will be, an essential diagnostic tool for tailoring personalized treatments, particularly after a
DAA-failure [12].
Emerging data have suggested that complex interactions between factors related to the
infecting virus (genotypes, viral load, RASs) and to the host (age, gender, degree of liver fibrosis,
alcohol consumption, etc.) would predict HCV treatment success and/or improve safety [8,18]. In fact,
significant associations have been reported between natural RASs and host genetic determinants in
the interferon lambda 3 (IFNL3) and 4 (IFNL4) genes, identified as predictors of Pegylated Interferon
and Ribavirin (PegIFN/RBV) response in chronic HCV [19–21].
Given that natural RASs that might confer DAAs resistance exhibit geographical differences in
their frequencies [22], the interpretation of the resistance profile is very complex, and the need of
resistance testing should be defined in each country. In this regard, the prevalence of natural RASs
has not been extensively studied in Argentina. Therefore, the aim of this study was to estimate the
prevalence of RASs within NS3, NS5A and NS5B genomic regions in DAA-naïve patients chronically
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infected with HCV genotype 1, by automated Sanger sequencing and Ion Torrent NGS, and to
determine their effect on therapy outcome. Additionally, virological, clinical and host genetic factors
were explored as predictors of the presence of baseline RASs.
2. Materials and Methods
2.1. Study Population
This study was approved a priori by the Ethics Committee on Research from the Hospital Italiano
of Buenos Aires and conducted in accordance with good clinical practice guidelines and the principles
of the Declaration of Helsinki.
From 2012 to 2014, consecutive DAA-naïve patients with genotype 1 chronic hepatitis C were
invited to participate in the study, which took place at the Hepatology Unit of the Hospital Italiano
of Buenos Aires. Serum and whole blood samples were collected from each patient, after obtaining
written informed consent.
Clinical data, such as gender, age and previous failure to PegIFN/RBV treatment, were recorded.
To evaluate the impact of baseline RASs on treatment outcome, SVR rates were documented in
those patients who underwent DAA prescription after recruitment and sample collection. Fibrosis
grade was staged either by biopsy or Transient Elastography by Fibroscan®(Echosens, Paris, France).
Plasma HCV RNA load was measured using Cobas®TaqMan®(Roche, Pleasanton, CA, USA), with a
detection limit of 15 IU/mL. HIV co-infection was diagnosed by ELISA (Dade Behring; Enzygnost anti
HIV-1/2 plus, Marburg GmbH, Germany) and confirmed by Western-blot (New Lab Blot-1, Bio-Rad,
Marnes-la-Coquette, France).
2.2. RT-PCR and Automated Sanger Sequencing
NS3, NS5A and NS5B genomic regions were partially amplified by previously described
RT-Nested PCR protocols specific for subtype 1a and 1b [23–25], covering positions involved in drug
resistance. PCR products were bi-directionally sequenced using the Big-Dye Termination chemistry
system (Applied Biosystems, Foster City, CA, USA).
HCV genotype and subtype were confirmed in each genomic region by phylogenetic analysis.
BioEdit (v.7.2.5) software [26] was used for sequence alignment. Phylogenetic trees were constructed
using the maximum-likelihood method in MEGA (v.6.0) [27], and visualized in TreeView v.1.6.6 [28].
Nucleotide sequences were deposited in GenBank under accession numbers MH733012–MH733240
and MK215006–MK215017.
2.3. NGS Sequencing
Amplicons were fragmented into 200 base pair (bp) pieces using Bioruptor®Sonication System
(Diagenode, Denville, NJ, USA). Fragments were nick repaired, adaptor ligated, and barcoded using
the Ion Neb Next Library kit (Life Technologies, Foster, CA, USA). Then, fragments were purified
by Agencourt®AMPure®XP magnetic beads (Beckman Coulter, Brea, CA, USA), the fragmentation
pattern was analyzed by semi-fluidic electrophoresis (Agilent®Bioanalyzer®, Santa Clara, CA, USA)
and libraries were diluted to obtain equimolar amounts. Emulsion PCR was carried out using the
Ion OneTouchTM 2.0 system (Life Technologies, Carlsbad, CA, USA) and the Ion PGMTM Template
Hi-Q™ OT2 200 kit (Thermo Fisher Scientific, Waltham, MA, USA), followed by an enrichment step.
Sequencing was performed on an Ion Torrent Personal Genome Machine (PGM) sequencer (Thermo
Fisher Scientific, Waltham, MA, USA) using the Ion PGM™ Hi-Q™ Sequencing Kit and the Ion 316 chip
(Thermo Fisher Scientific, Waltham, MA, USA).
2.4. RASs Analysis
RASs were defined as a change in the RNA sequence associated to in vivo (with treatment failure)
and/or in vitro phenotypic assays (to confer more than 2.5-fold change in drug susceptibility in
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comparison to the wild-type reference strain). RASs summarized by a recent systematic review [15]
were selected for the analysis in this study. Overall, nine NS5A (24, 28, 30, 31, 32, 38, 58, 92 and 93),
three NS5B (159, 237 and 282) and 14 NS3 positions (36, 41, 43, 54, 55, 56, 80, 122, 155, 156, 158, 168,
170 and 175) were analyzed in this study. Nucleotide sequences obtained from automated Sanger
sequencing were aligned and compared with reference sequences for subtype 1a (AF009606) and 1b
(AJ238799), using BioEdit (v.7.2.5) software [26].
All NGS reads were trimmed and aligned with the previously mentioned reference sequences
using the Smith–Waterman algorithm, included in the Torrent Suite™ software (Thermo Fisher
Scientific, Waltham, MA, USA). The plugins Variant Caller and Coverage Analyzer, both available in
this software, were used for analysis of sequence variants and coverage, respectively. Low stringency
parameters were used to identify variants, as previously reported [17]. Sequence data were visually
confirmed with the Integrative Genomics Viewer and any sequence, alignment, or variant call error
artifacts were discarded.
2.5. HCV Quasispecies Analysis
Sequencing errors induced by PCR and ultra-deep sequencing would complicate the analysis
of viral populations and result in inflated estimates of quasispecies heterogeneity. To avoid such
misinterpretation, all necessary precautions in sample preparation, RNA extraction, and amplification
were taken into account [29], and PCR bias was avoided as previously reported [30]. In addition,
ShoRAH (v.0.8) software, which applied a probabilistic Bayesian approach to minimize the effects of
errors, was used [31].
The quasispecies complexity of NS3, NS5A and NS5B was determined by calculating: Nucleotide
mutation frequency (Pn) and normalized Shannon entropy (Sn). Pn was calculated as the total number
of polymorphic sites divided by the total number of nucleotides sequenced; considering that the
variability of the quasispecies increased as Pn increased. The measure of the Shannon entropy, defined
in terms of the probabilities of different sequences that can appear at a given time point was calculated
using the formula S = −Σi(pi ln pi), where pi is the frequency of each variant in the viral quasispecies.
The normalized entropy, Sn, was calculated as Sn = S/ln N, where N is the total number of sequences
analyzed in each sample. Sn theoretically varies from 0 (no diversity) to 1 (maximum diversity) [32].
2.6. SNPs Genotyping
SNPs rs12979860 (IFNL3) and rs368234815 (IFNL4) were genotyped by PCR [21] followed by
bi-directional sequencing using Big-Dye Termination chemistry system. BioEdit (v.7.2.5) software [26]
was used to discriminate between homozygotes and heterozygotes.
2.7. Evaluated Variables and Statistical Analyses
For descriptive statistics, mean and standard deviation (SD) or absolute number and percentages
were used. The statistical analysis of data was performed by means of contingency tables using
Fisher exact probability test for categorical variables and Mann–Whitney U test for continuous
variables. Univariate and multivariate logistic analyses were performed to identify variables that
were independently associated with the presence of RASs in each genomic region. All significant
parameters in the univariate analysis were included in the multivariate analysis. The virological
variables that were explored to be associated with the presence of RASs were HCV subtypes, viral
load and quasispecies complexity. Age, gender, METAVIR score and previous failure to PegIFN/RBV
treatment were the clinical variables analyzed to be associated with RASs. Host SNPs in IFNL3/IFNL4
genes were also explored. Statistical analyses were performed with the Statistical Package for the
Social Sciences software (v.18.0) (SPSS, Chicago, IL, USA) and significant differences were considered
only for p < 0.05.
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3. Results
3.1. Patients’ Characteristics
A total of 86 consecutive DAA-naïve patients chronically infected with HCV genotype 1
(33 subtype 1a and 53 subtype 1b) were included in the study. The clinical, virological and host
genetic characteristics of the patients are shown in Table 1.
Table 1. Main characteristics of the Hepatitis C Virus (HCV) genotype 1 patients recruited in this study.
Characteristics
All
(n = 86)
HCV Subtype
p ValueHCV GT1a
(n = 33, 38.4%)
HCV GT1b
(n = 53, 61.6%)
HCV viral load, log10 copies/mL, mean ± SD 6.1 ± 3.8 6.2 ± 3.9 6.1 ± 3.5 0.71
Age, years, mean ± SD 54.7 ± 11.0 50.6 ± 8.9 57.3 ± 11.5 0.005
Male, no. (%) 52 (60.5) 24 (72.7) 28 (52.8) 0.07
METAVIR Score, no. (%)
F0/F1 38 (44.2) 11 (33.3) 27 (50.9)
F2 18 (20.9) 10 (30.3) 8 (15.1) 0.1
F3 10 (11.6) 6 (18.2) 4 (7.5)
F4 20 (23.3) 6 (18.2) 14 (26.5)
HIV co-infection, no. (%) 5 (5.8) 3 (9.1) 2 (3.7) 0.37
Previous failure to PegIFN/RBV treatment, no.
(%) 31 (36.1) 12 (36.4) 19 (35.9) 1
IFNL3 SNP rs12979860, no. (%)
CC 18 (20.9) 9 (27.3) 9 (17)
CT 57 (66.3) 19 (57.6) 38 (71.7) 0.39
TT 11 (12.8) 5 (15.1) 6 (11.3)
IFNL4 SNP rs368234815, no. (%)
TT/TT 18 (20.9) 9 (27.3) 9 (17)
TT/∆G 57 (66.3) 19 (57.6) 38 (71.7) 0.39
∆G/∆G 11 (12.8) 5 (15.1) 6 (11.3)
Statistically significant p values are in bold.
3.2. Prevalence of RASs in NS5A Protein
The NS5A region was successfully amplified in 84 (97.7%) samples: 51 (60.7%) belonged to HCV
subtype 1b and 33 (39.3%) to subtype 1a. The latter sequences clustered into clade 1 (25 sequences;
75.8%) and clade 2 (eight sequences; 24.2%) (Supplementary Figure S1). No difference was observed in
the presence of RASs between both clades: 8/25 (32%) in clade 1 and 4/8 (50%) in clade 2 (p = 0.42).
A total of 14 (16.7%) sequences exhibited RASs among the 84 analyzed patients, being the
prevalence significantly higher in subtype 1b (13/51; 25.5%) when compared to subtype 1a (1/33; 3%)
(p = 0.007).
Among the 51 subtype 1b sequences, RASs L28M (2%), L31M (2%), L31F (2%), and R30Q (13.7%)
considered as primary resistance mutations to DCV, ELB, LDV and OMV, were identified. Substitutions
detected at positions 58—which confers resistance to VLP—and 92—associated with resistance to LDV
and OMV—were P58R/T (4%) and A92T (2%), respectively (Table 2).
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Table 2. Frequency of resistance-associated substitutions (RASs) in the NS5A protein by automated
Sanger sequencing data.
Genotype Reference NS5A
Position
RASs Frequency
K24 R -
M28 A/G/T/S/V M28V (1/33; 3%)
Q30 D/E/G/H/K/L/N/R/Y -
L31 F/I/M/V -
P32 L -
1a S38 F -
H58 D -
A92 K/T -
Y93 C/F/H/L/N/R/S/T/W -
Q24 K -
L28 M/T L28M (1/51; 2%)
R30 G/H/Q/S R30Q (7/51; 13.7%)
1b L31 F/I/M/V L31M (1/51; 2%)
L31F (1/51; 2%)
P58 A/D/L/R/S/T P58R (1/51; 2%)
P58T (1/51; 2%)
A92 K/T A92T (1/51; 2%)
Y93 C/H/I/N/R/S/T -
Among the 33 subtype 1a strains, the primary resistance mutation M28V, related to resistance to
LDV and OMV, was observed in one (3%) sample. (Table 2).
No combinations of multiple RAS were observed in subtype 1a, whereas in subtype 1b, one patient
(2%) carried two mutations being the genetic profile R30Q+P58R.
3.3. Prevalence of RASs in NS5B Polymerase
The NS5B region was successfully amplified in 79 (91.9%) samples: 49 (62%) belonged to HCV
subtype 1b and 30 (38%) to subtype 1a. The latter sequences split into clade 1 (22 sequences; 73.3%)
and clade 2 (eight sequences; 26.7%) (Supplementary Figure S2). No difference was observed in the
presence of RASs between both clades: 4/22 (18.2%) in clade 1 and 3/8 (37.5%) in clade 2 (p = 0.34).
Screening and analysis of NS5B residues 1 to 300 detected RASs at positions 159 and 282 in seven
(8.9%) of the 79 sequences, all of them ascribed to subtype 1b. Therefore, the prevalence of RASs was
significantly higher in subtype 1b (7/49; 14.3%) when compared to subtype 1a (0%) (p = 0.04).
Among the 49 subtype 1b sequences, five (10.2%) harbored the L159F variant, associated with a
lower response to SOF. Although the major mutation S282T, which confers high-level resistance to
SOF, was not observed, RASs S282G (4.1%) was detected (Table 3).
No combinations of multiple RASs were observed in subtype 1a- or 1b-infected patients.
Table 3. Frequency of RASs in the NS5B polymerase by automated Sanger sequencing data.
Genotype Reference NS5B Position RASs Frequency
L159 F -
1a E237 G -
S282 R/T -
1b
L159 F L159F (5/49; 10.2%)
S282 G/T S282G (2/49; 4.1%)
3.4. Prevalence of RASs in NS3 Protease
The NS3 gene was successfully amplified in 79 (91.9%) samples: 50 were ascribed to HCV subtype
1b (63.3%) and 29 to subtype 1a (36.7%). The latter sequences clustered into clade 1 (22 sequences;
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75.9%) and clade 2 (seven sequences; 24.1%) (Supplementary Figure S3). No difference was observed in
the presence of RASs between both clades: 5/22 (22.7%) in clade 1 and 3/7 (42.9%) in clade 2 (p = 0.36).
RASs were found in 22 (27.8%) of the 79 sequences, and their overall prevalence was higher in
subtype 1b (18/50; 36%) than in subtype 1a (4/29; 13.8%) (p = 0.04).
Among the 29 subtype 1a strains, the clinically relevant RASs Q80K, associated with resistance to
SMV, GZR and PTV, was detected only in one (3.4%) sample ascribed to subtype 1a clade 1. Substitution
T54S, associated with resistance to ASV and SMV, was found in one (2%) sequence; as well as RAS
V36L, which confers resistance to SMV, GZR and PTV, and I170V associated with resistance to SMV
(Table 4).
Table 4. Frequency of RASs in the NS3 protease by automated Sanger sequencing data.
Genotype Reference NS3
Position
RASs Frequency
V36 A/G/M/L V36L (1/29; 3.4%)
Q41 R -
F43 S -
T54 A/S T54S (1/29; 3.4%)
Y56 F/H -
1a Q80 K/R Q80K (1/29; 3.4%)
S122 R -
R155 I/G/K/N/Q/S/T/W -
A156 G/L/M/S/T/V -
V158 A -
D168 A/C/E/F/G/H/I/K/L/N/R/S/T/V/Y -
I170 T/V I170V (1/29; 3.4%)
V36 A/G/M -
Q41 R -
F43 L/S/V -
T54 A/S T54S (1/50; 2%)
V55 A/I -
Y56 F/H Y56F (8/50; 16%)
1b Q80 K/L/R Q80K (1/50; 2%)
Q80R (1/50; 2%)
S122 D/G/R/T S122G (4/50; 8%)
S122T (2/50; 4%)
R155 K/G/L/T/Q/W R155K (1/50; 2%)
A156 G/S/T/V -
D168 A/C/E/F/G/H/I/K/N/Q/T/V/Y -
V170 A/T -
M175 L -
Among the 50 subtype 1b strains, eight (16%) sequences presented the mutation Y56F associated
with resistance to GRZ, and six (12%) exhibited the substitutions S122G/T associated with resistance
to SMV. Variants at position 80 were detected in two (4%) samples: The primary resistance RAS
Q80K and the low-level resistance RAS to SMV Q80R. Substitution T54S which confers resistance to
first-generation protease inhibitors, and R155 associated with resistance to first- and second-generation
protease inhibitors, were found each in one (2%) sequence (Table 4).
No combinations of multiple RASs were observed in subtype 1a- or 1b-infected patients.
3.5. Comparison of NGS and Direct Sequencing Results
The NS5A, NS5B and NS3 genes were successfully sequenced by NGS in 76 (90.5%), 72 (91.1%)
and 72 (91.1%) of the samples characterized by automated Sanger sequencing, respectively. A mean
of 12,259,169, 10,968,036 and 19,235,648 bp in the NS5A, NS5B and NS3 genes were mapped onto the
reference sequences, and an overall average coverage depth of 889x, 859x and 987x was achieved
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for each region, respectively. An average of 60,676, 59,412 and 90,748 reads of the NS5A, NS5B and
NS3 regions were aligned and compared with reference sequences for each subtype, respectively.
Deep sequencing yielded a median of 11,650, 10,870 and 12,340 sequences per sample in the NS5A,
NS5B and NS3 genomic regions, respectively.
All RASs called by automated Sanger sequencing were confirmed by the NGS platform.
Furthermore, deep sequencing (interpretative cut-off of ≥1%) identified additional RASs with
frequencies between 2% and 21% among the patient’s viral quasispecies, in NS5A (8/76; 10.5%)
and NS3 (9/72; 11.1%) but not in NS5B (Table 5).
Table 5. Prevalence of RASs in the NS5A and NS3 regions detected only by Next Generation Sequencing.
Genomic
Region RASs Patient No. HCV Subtype
Mutation Frequency
in Viral Quasispecies
K24R 87 1a K24R (2%)
Q24K 80 1b Q24K (6.7%)
M28A/G/T/S/V 4 1a M28V (21%)
NS5A R30G/H/Q/S 10 1b R30H (5.8%)
L31F/I/M/V 24 1b L31M (5.3%)
P58A/D/L/R/S/T 97 1b P58S (3.4%)
A92K/T 120 1b A92T (4.2%)
Y93C/F/H/L/N/R/S/T/W 4 1a Y93H (3%)
F43L/S/V 108 1b F43S (2%)
T54A/S 62 1b T54S (3.5%)
Y56F/H 106 1b Y56F (3.9%)
90 1b Y56F (7.3%)
NS3 74 1b Y56H (4.1%)
Q80K/L/R 40 1b Q80L (21%)
S122D/G/R/T 49 1b S122G (4.8%)
88 1b S122G (12%)
76 1b S122T (3.9%)
3.6. Assessment of HCV Quasispecies Diversity
The viral population parameters of complexity of the NS5A, NS5B and NS3 genes sequenced by
NGS, are summarized in Table 6.
Table 6. Mean genetic complexity in each viral genomic region by HCV subtype.
Genomic
Regions
HCV Subtype
(n=)
Mutations 1/Nucleotides
Sequenced
Nucleotide
Mutation
Frequency 2 p Value
Normalized
Shannon Entropy 3 p Value
1a 1b 1a 1b 1a 1b 1a 1b
NS5A 32 44 50/711 75/715 0.07 0.1 0.002 0.011 0.017 0.11
NS5B 30 42 73/916 78/945 0.08 0.08 0.86 0.014 0.017 0.85
NS3 29 43 74/1007 132/1300 0.07 0.1 0.002 0.015 0.017 0.19
1 Mutations are those that vary when compared to the corresponding reference sequences; 2 the nucleotide mutation
frequency is the total number of mutations divided by the total number of nucleotides sequenced; 3 the normalized
Shannon entropy is calculated as Sn = −[∑i (pi ln pi)]/ln N, in which pi is the proportion of each sequence of the
mutant spectrum and N is the total number of sequences compared. Statistically significant p values are in bold.
No significant associations were observed when these parameters were compared among the
three analyzed HCV genomic regions. However, the nucleotide mutation frequencies for subtype 1a
in NS3 and NS5A regions were significantly lower than those for subtype 1b (p = 0.002). Nucleotide
mutation frequencies in the NS5B region as well as entropy values for all analyzed genomic regions
were similar between subtype 1a and 1b (Table 6).
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Table 7. Univariate and multivariate logistic regression analyses to identify independent factors associated with the presence of RASs in the NS5A gene (A), the NS5B
region (B) and the NS3 gene (C).
A
Patients Characteristics
RASs
(n = 14)
No RASs
(n = 70)
Univariate Analysis Multivariate Analysis
p Value p Value OR (95% CI)
Male gender, no. (%) 9 (64.3) 41 (58.6) 0.77
Age (years), mean ± SD 53.4 ± 5.1 56.5 ± 4.9 0.77
HCV viral load (log10), mean ± SD 6.2 ± 3.2 6.1 ± 3.3 0.47
HCV subtype 1b, no. (%) 13 (92.9) 38 (54.3) 0.007 0.03 16.2 (1.3–20.6)
METAVIR Score F4, no. (%) 6 (42.9) 13 (18.6) 0.07
HIV co-infection, no. (%) 2 (14.3) 3 (4.3) 0.19
Previous failure to PegIFN/RBV treatment, no. (%) 8 (57.1) 23 (32.9) 0.13
IFNL3 SNP (rs12979860) CC genotype a, no. (%) 10 (71.4) 8 (11.4) 0.0001 0.0005 16.8 (3.4–8.2)
Normalized Shannon Entropy b, mean ± SD (×1000) 17 ± 8.7 10.3 ± 3.6 0.02 0.01 2.16 (1.3–4.6)
Nucleotide Mutation Frequency b, mean ± SD (×1000) 9.8 ± 4.5 6.3 ± 2.1 0.004 0.009 4.7 (1.4–15.2)
Statistically significant p values are in bold. OR: Odds Ratio; 95% CI: 95% confidence interval. a IFNL4 (rs368234815) was not included in the analysis due to its high linkage disequilibrium
with IFNL3 (rs12979860) SNP in the analyzed population (Table 1). b Calculated on 76 samples.
B
Patients Characteristics
RASs
(n = 7)
No RASs
(n = 72)
Univariate Analysis Multivariate Analysis
p Value p Value OR (95% CI)
Male gender, no. (%) 5 (71.4) 43 (59.7) 0.7
Age (years), mean ± SD 53.5 ± 5.4 50.3 ± 5.6 0.52
HCV viral load (log10), mean ± SD 6.1 ± 2.2 5.9 ± 2.6 0.88
HCV subtype 1b, no. (%) 7 (100) 42 (58.3) 0.04 0.99 1.7 (0.40–1.41)
METAVIR Score F4, no. (%) 3 (42.9) 17 (23.6) 0.36
HIV co-infection, no. (%) 1 (14.3) 4 (5.55) 0.38
Previous failure to PegIFN/RBV treatment, no. (%) 5 (71.4) 29 (40.3) 0.13
IFNL3 SNP (rs12979860) CC genotype a, no. (%) 2 (28.6) 12 (16.7) 0.6
Normalized Shannon Entropy b, mean ± SD (×1000) 8.9 ± 2.3 9.6 ± 1.4 0.4
Nucleotide Mutation Frequency b, mean ± SD (×1000) 6.2 ± 3.9 2.9 ± 3.1 0.03 0.98 1 (0.78–1.3)
Statistically significant p values are in bold. OR: Odds Ratio; 95% CI: 95% confidence interval. a IFNL4 (rs368234815) was not included in the analysis due to its high linkage disequilibrium
with IFNL3 (rs12979860) SNP in the analyzed population (Table 1). b Calculated on 72 samples.
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Table 7. Cont.
C
Patients Characteristics
RASs
(n = 22)
No RASs
(n = 57)
Univariate Analysis Multivariate Analysis
p Value p Value OR (95% CI)
Male gender, no. (%) 17 (77.2) 36 (63.2) 0.29
Age (years), mean ± SD 55.1 ± 4.8 52.5 ± 6.1 0.59
HCV viral load (log10), mean ± SD 6.2 ± 3.1 5.9 ± 1.9 0.27
HCV subtype 1b, no. (%) 18 (81.8) 32 (56.1) 0.04 0.57 1.51 (0.36–6.4)
METAVIR Score F4, no. (%) 8 (36.4) 12 (21.05) 0.25
HIV co-infection, no. (%) 2 (9.1) 3 (5.3) 0.61
Previous failure to PegIFN/RBV treatment, no. (%) 10 (45.4) 16 (28.1) 0.18
IFNL3 SNP (rs12979860) CC genotype a, no. (%) 12 (54.5) 10 (17.5) 0.002 0.01 6.3 (1.5–25.8)
Normalized Shannon Entropy b, mean ± SD (×1000) 21.2 ± 1.5 15.8 ± 2.9 0.33
Nucleotide Mutation Frequency b, mean ± SD (×1000) 7.9 ± 2.6 6.8 ± 4.1 0.21
Statistically significant p values are in bold. OR: Odds Ratio; 95% CI: 95% confidence interval. a IFNL4 (rs368234815) was not included in the analysis due to its high linkage disequilibrium
with IFNL3 (rs12979860) SNP in the analyzed population (Table 1). b Calculated on 72 samples.
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3.7. Factors Related to the Presence of Baseline RASs
In univariate analyses, several factors were significantly associated with the presence of baseline
RASs in the NS5A, NS5B and NS3 regions (Table 7).
In a multivariate logistic regression model, HCV subtype 1b, IFNL3 CC genotype and values above
the median of Shannon entropy and nucleotide mutation frequency were identified as independent
predictors of the presence of baseline RASs in the NS5A gene. Among these, IFNL3 CC genotype
was the factor with the highest predictive value (p = 0.0005). In the NS3 gene, this host genetic factor
was also identified as the only independent predictor of the presence of RASs at baseline (p = 0.01).
No factor was independently associated with the presence of RASs in the NS5B genomic region after
the multivariate analysis (Table 7).
3.8. Effect of Baseline RASs on Treatment Outcome
Sixty of the 86 (69.8%) recruited patients (28 subtype 1a and 32 subtype 1b) were treated with
DAAs after enrolment in this study. Most of them (43/60; 71.7%) received SOF based combination:
SOF + DCV for 12 weeks (28/43, 65.1%), SOF + DCV for 24 weeks (13/43, 30.2%), SOF + SMV for
12 weeks (1/43, 2.3%), and SOF + LDV for 12 weeks (1/43, 2.3%). One patient received DCV +
Peg-IFN/RBV for 24 weeks (1/60, 1.7%) and the remaining 16 patients were treated for 24 to 48 weeks
during 2012 to 2013 with triple therapy including Peg-IFN/RBV in combination with a first-generation
NS3 protease inhibitor: Four received BOC + Peg-IFN/RBV (4/60; 6.7%) and 12 TVR + Peg-IFN/RBV
(12/60; 20%).
Overall, 93.3% (56/60) of the patients achieved SVR. Among them, 27 patients (27/56; 48.2%)
exhibited at baseline a RAS (or a combination of RASs) related to the DAA-regimen. Treatment failure
was observed in four (6.7%) cirrhotic and treatment-experienced patients (one subtype 1a and three
subtype 1b) who relapsed after receiving triple therapy. One of the subtype 1b patients had a low-level
baseline RAS (S122G) to protease inhibitors.
4. Discussion
The World Health Organization (WHO) has declared that HCV should be eliminated as a
public health threat by 2030 [2]. Although DAAs seem a promising tool for viral elimination, HCV
treatment fails in approximately 2.5% to 5% of patients and this may often occur in the presence
of RASs [1]. Moreover, it has been reported that the frequencies of RASs differ between geno- and
subtypes, geographical region and method of sequencing [33]. In addition, several viral, host and
treatment factors can influence the emergence of RASs [18]. Therefore, in order to reach the worldwide
elimination goals, RAS prevalence should be evaluated in individual countries or regions.
In this study, the combined results from both sequencing methods revealed that the frequency of
natural RASs varied according to the analyzed viral region, as RASs were more frequently observed in
the NS3 when compared to their frequency in the NS5A (39.2% vs. 25%, respectively; p = 0.06) and in
the NS5B genes (39.2% vs. 8.9%; p < 0.0001).
This disparity in the prevalence of RASs between the three genomic regions is a possible reflection
of the fact that the substitution rates in the different proteins may be constrained by the function
that each one of them fulfills in the biology of the HCV. Since the genetic variability is not evenly
distributed across the viral genome [34], different evolutionary processes shape the different genetic
barriers for the development of resistance of each DAA family, which are similar between NS5A and
NS3 protease, but higher for NS5B polymerase [34].
In the NS3 and NS5A regions, the frequencies of natural RAS were higher than those observed in
previous studies [10,35], but similar to those reported in Argentina for NS3 [25] and in Brazil [17,36,37]
when taking into consideration the sequencing method and cut-off value used. Notably, when the
analysis was limited to amino acid substitutions associated with a clinically relevant level of resistance
(defined as “likely resistant”), their prevalence was lower in both genomic regions when compared
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to other studies [10,22,35,38]. In this regard, in the NS5A protein, combining the results from both
sequencing methods, mutations M28V and L31M were only detected in two subtype 1a and two
subtype 1b-infected patients, respectively. Moreover, RAS Y93H, which confers high-level resistance to
DCV, OMV, LDV and ELB [39], was observed in one subtype 1a-infected patient at a low frequency
(3%) only after performing NGS. In the NS3 region, the clinically important RAS Q80K was only
detected in one patient belonging to subtype 1a clade 1. This finding is in agreement with amino acid
signature analyses from United States and Europe sequences in which Q80K polymorphism was only
found in subtype 1a clade 1 and not clade 2 [40,41].
The low prevalence of the clinically relevant RASs in the NS3 and NS5A regions in this study
contrasts with results from Asia, Europe and USA [35,38,42–44], but it is similar to Argentinean
and Brazilian reports [17,25,36,37]. The reasons for this discrepancy remain unclear as there is still
little information about the genetic variability of the viral genes of HCV isolates from Latin America.
However, this finding could be associated to geographical factors, as previously suggested [45,46].
In the NS5B region, the prevalence of RASs was lower than those reported by other studies [35,47].
None of the patients carried the S282T mutation, which is the signature substitution associated with
resistance to SOF in vitro for all HCV genotypes [38]. This finding is in agreement with previous
studies which reported that S282T is rarely (<1%) selected in patients treated with a SOF-based regimen
and is not detected in treatment-naïve genotype 1 patients [42].
In this study, natural substitutions were detected at baseline in both subtypes, with a higher
prevalence of RASs among subtype 1b samples in all three HCV genomic regions. This finding is in
agreement with studies carried out in Italy [42], Argentina [25] and Brazil [17,35,45,48]; whereas a
higher prevalence of RASs in subtype 1a sequences was observed in Europe and USA [10,22,49,50] and
in two reports from Uruguay in which the number of analyzed subtype 1b sequences was relatively
low [51,52].
The higher presence of Q80K among subtype 1a samples reported in Europe and USA, as well as
the low prevalence of this subtype and this mutation among the samples of this study [4,25] could be
possibly related to the different prevalence of RASs in each region. These geographic discrepancies
highlight the genetic diversity present in both the natural RASs found in Latin American countries and
the evolutionary relationships between Argentinean and other worldwide isolates, probably linked to
the Italian immigration occurred in the 19th century.
Regarding the differences observed between subtypes, the nucleotide mutation frequencies in the
NS3 and NS5A regions revealed that the genetic diversity was significantly higher among subtype
1b-infected patients compared to those infected with subtype 1a. Subtype 1b patients were, on
average, older than those infected with subtype 1a (Table 1) and may have been infected—and possibly
transmitting HCV—for longer periods of time [53], leading to a higher diversity in the viral genome.
Finally, the higher prevalence of multiple RASs in subtype 1b genomes could enhance their replication
capacity, as was previously reported [54,55]. Taking this into account, HCV subtype 1b infection may
have a more unfavorable treatment outcome in Argentina than the expected in other geographical
regions, particularly with some DAA regimens. However, the baseline presence of RASs in both HCV
subtypes did not appear to affect therapy outcome on a limited sample of patients treated with DAAs
in this study.
The need to routinely test for RASs at baseline has been recommended for Q80K in subtype 1a
prior to using SMV in interferon-containing regimens, and in patients with cirrhosis that are going to
be treated with SOF and SMV. For NS5A inhibitors, it is recommended to test for RASs in subtype
1a patients when using GZR + EBR [12]. The results presented herein suggest that routine testing for
RASs at baseline would not be necessary for subtype 1a patients in this population, as their frequencies
are low. However, the development of a resistance monitoring system is required as this scenario may
change in the near future.
It has been reported that not only the presence of a particular RAS but also the RAS dominancy
(>15% to 25%) in the patient’s quasispecies has an impact on treatment outcome [56,57], although a
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recent study suggests that minority RASs present at much lower than 15% may also be relevant for
treatment planning [58]. In this regard, this is the first report in Argentina that screened HCV drug
resistance using NGS. This technology revealed RASs—not detected by automated sequencing—in
10.5% and 11.1% of the NS5A and NS3 samples. Among them, only two RASs were detected at a
frequency above 15% among the patient’s viral quasispecies: M28V (with a frequency of 21%) in NS5A
and Q80L (with a frequency of 21%) in NS3. This finding supports the fact that deep sequencing has
not been proven clinically relevant for RASs testing [59]. Indeed, NGS methodology is costly, too
laborious, and technically challenging for many laboratories [60] and, thus, NGS could not yet be
ready for routine clinical practice in Argentina.
Although Sanger automated sequencing is generally limited to the detection of variants with
greater than 20% of prevalence [16], the two RASs mentioned above could not be detected by automated
sequencing. This lack of correlation between both sequencing methods was probably due to the fact
that both samples exhibited low viral loads (3.2 log10 copies/mL), as it was previously reported [61]. In
fact, it has been estimated that the efficiency of RNA extraction and cDNA synthesis is 1% to 10% [62];
thus, in low viral load samples, the small number of molecules present in the cDNA could be better
examined by the higher analytical sensitivity of NGS [63].
Regarding host factors, it has been reported that the IFNL4 TT genotype, which has a more
efficient antiviral response to HCV infection, is strongly associated with RAS Y93H in the subtype
1b NS5A protein, resulting in selection for viral adaptations [19,21]. In this study, univariate and
multivariate analyses revealed that the IFNL3 CC genotype was identified as an independent predictor
of the presence of RASs at baseline in NS5A and NS3 genomic regions. Therefore, differences in the
frequency of NS5A and NS3 RASs could reflect disparities in the selection pressure against HCV due
to genetic variations within the IFNL3/4 locus.
Finally, this study has certain limitations that need to be considered. First, NS3, NS5A and
NS5B genes could not be amplified in some patients due to the low volume of stored serum and/or
RNA samples. Second, the number of analyzed sequences was not so large. However, other studies
included a similar—or even smaller—number of patients [46,51,52]. Finally, this study recruited only
genotype 1 patients from Buenos Aires and the metropolitan region, and thus excluded patients
infected with other genotypes or from distant areas of Buenos Aires, where the ancestry composition of
the population and the prevalence of host genetic factors differ [64]. Therefore, these findings should
not be generalized or transferable to the whole country.
5. Conclusions
Decisions regarding which combinations of DAAs to use remain challenging [65,66]. This study
depicts a current scenario on DAA resistance in Buenos Aires, Argentina. In summary, the frequencies
of natural NS5A and NS3 substitutions were similar than those previously reported in this geographic
region. In the NS5B region, the prevalence of RASs was lower than those previously reported. Notably,
the prevalence of clinically relevant RASs in the three analyzed genes was lower than those observed
around the world. Although tested on a limited sample of patients in this study, the baseline presence
of RASs in both HCV subtypes did not appear to affect therapy outcome. Despite the fact that
NGS allowed a more complete analysis of RASs, its usefulness may be limited in this population.
These results support the need to define the resistance testing in each country since the RASs have
very different worldwide prevalence.
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Figure S1: Maximum-likelihood phylogenetic tree (GTR+Γ+I model for nucleotide substitutions) including
48 references sequences (in black) and the 84 HCV-NS5A samples of this study (in red). The numbers at
each node correspond to bootstrap values obtained with 100 replicates (values lower than 70 are not shown);
Figure S2: Maximum-likelihood phylogenetic tree (GTR+Γ+I model for nucleotide substitutions) including 48
references sequences (in black) and the 79 HCV-NS5B samples of this study (in red). The numbers at each node
correspond to bootstrap values obtained with 100 replicates (values lower than 70 are not shown); Figure S3:
Maximum-likelihood phylogenetic tree (GTR+Γ+I model for nucleotide substitutions) including 48 references
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sequences (in black) and the 79 HCV-NS3 samples of this study (in red). The numbers at each node correspond to
bootstrap values obtained with 100 replicates (values lower than 70 are not shown).
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